Stifel Reaffirms Buy on Alcon (ALC), Highlights Eye Care Leader's Growth Potential

Alcon Inc. (NYSE:ALC) ranks among the best medical stocks to buy according to analysts. On July 10, Stifel reaffirmed its Buy rating for Alcon Inc. (NYSE:ALC) with a $100 price rating. According to the research firm, one of the main reasons for the ongoing optimism is Alcon’s dominant market position in the ophthalmology industry.

Stifel emphasizes Alcon’s position in what it calls an “attractive” industry category and sees the company as a “core holding” in its coverage umbrella. According to the firm, Alcon Inc. (NYSE:ALC) is currently seeing sustainable growth in the mid-single-digit percentage range or higher.

Stifel’s investment case for the eye care company was further backed by Alcon’s potential for margin expansion.

One of the most notable eye care companies, Alcon Inc. (NYSE:ALC) focuses on developing a variety of eye care products. The company offers a range of products, including intraocular lenses, surgical packs, microscopes, visualization systems, and medications to treat allergies and glaucoma.

While we acknowledge the potential of ALC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.